Revelation Biosciences Inc (REVB)
2.23
-0.15
(-6.30%)
USD |
NASDAQ |
May 08, 16:00
2.24
+0.01
(+0.45%)
After-Hours: 20:00
Revelation Biosciences Enterprise Value: -8.105M for May 7, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 07, 2024 | -8.105M |
| May 06, 2024 | -8.154M |
| May 03, 2024 | -8.122M |
| May 02, 2024 | -8.154M |
| May 01, 2024 | -8.481M |
| April 30, 2024 | -8.551M |
| April 29, 2024 | -8.53M |
| April 26, 2024 | -8.432M |
| April 25, 2024 | -8.498M |
| April 24, 2024 | -8.579M |
| April 23, 2024 | -8.612M |
| April 22, 2024 | -8.644M |
| April 19, 2024 | -8.334M |
| April 18, 2024 | -8.334M |
| April 17, 2024 | -8.481M |
| April 16, 2024 | -8.873M |
| April 15, 2024 | -9.012M |
| April 12, 2024 | -8.595M |
| April 11, 2024 | -8.203M |
| April 10, 2024 | -8.220M |
| April 09, 2024 | -8.024M |
| April 08, 2024 | -7.746M |
| April 05, 2024 | -7.632M |
| April 04, 2024 | -7.550M |
| April 03, 2024 | -7.746M |
| Date | Value |
|---|---|
| April 02, 2024 | -7.762M |
| April 01, 2024 | -7.648M |
| March 28, 2024 | -7.518M |
| March 27, 2024 | -8.024M |
| March 26, 2024 | -7.746M |
| March 25, 2024 | -8.089M |
| March 22, 2024 | -8.122M |
| March 21, 2024 | -7.991M |
| March 20, 2024 | -8.024M |
| March 19, 2024 | -8.269M |
| March 18, 2024 | -8.089M |
| March 15, 2024 | -11.04M |
| March 14, 2024 | -11.06M |
| March 13, 2024 | -10.96M |
| March 12, 2024 | -10.75M |
| March 11, 2024 | -10.66M |
| March 08, 2024 | -10.64M |
| March 07, 2024 | -10.64M |
| March 06, 2024 | -10.80M |
| March 05, 2024 | -10.73M |
| March 04, 2024 | -10.64M |
| March 01, 2024 | -10.55M |
| February 29, 2024 | -10.54M |
| February 28, 2024 | -10.36M |
| February 27, 2024 | -10.63M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-13.02M
Minimum
Apr 12 2023
118.19M
Maximum
Jan 12 2022
-0.4195M
Average
-1.393M
Median
Nov 09 2022
Enterprise Value Benchmarks
| Cardiff Oncology Inc | 75.93M |
| Ocular Therapeutix Inc | 759.74M |
| Ocugen Inc | 367.34M |
| Cue Biopharma Inc | 65.69M |
| Solid Biosciences Inc | 271.25M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.203M |
| Total Expenses (Quarterly) | 2.326M |
| EPS Diluted (Quarterly) | -8.327 |
| Earnings Yield | 1.36K% |